2014
Cardiovascular Safety of Stimulants in Children with Attention-Deficit/Hyperactivity Disorder: A Nationwide Prospective Cohort Study
Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular Safety of Stimulants in Children with Attention-Deficit/Hyperactivity Disorder: A Nationwide Prospective Cohort Study. Journal Of Child And Adolescent Psychopharmacology 2014, 24: 302-310. PMID: 24956171, PMCID: PMC4137345, DOI: 10.1089/cap.2014.0020.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderProspective cohort studyCardiovascular eventsCohort studyDose-response relationshipStimulant treatmentCardiovascular safetyHazard ratioRisk factorsFirst nationwide cohort studyNationwide prospective cohort studyPossible dose-response relationshipUnique personal identification numberCardiovascular adverse eventsCardiovascular risk factorsHyperactivity disorderNationwide cohort studyNational health registersStimulant usersPopulation-based sampleAdverse eventsHealth registersProspective followCox regressionPotential confounders
2009
Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 884-893. PMID: 19625978, PMCID: PMC3943246, DOI: 10.1097/chi.0b013e3181b26e9f.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-AgonistsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityChildComorbidityContraindicationsDose-Response Relationship, DrugDouble-Blind MethodHumansMethylphenidatePropylaminesPsychotropic DrugsRandomized Controlled Trials as TopicTic DisordersTourette SyndromeConceptsAlpha-2 agonistsAttention-deficit/hyperactivity disorderTic symptomsComorbid ticsSupratherapeutic dosesTic disordersADHD symptomsTreatment of ADHDHyperactivity disorderPlacebo-controlled trialEfficacy of medicationsStandardized mean differenceEvidence-based treatmentsHalf of childrenComorbid tic disordersPrimary outcomeDifferent medicationsPsychostimulant medicationPubMed searchTic severityTourette syndromePackage insertsDrug AdministrationAtomoxetineSymptomsMeta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2009, 15: 850-855. PMID: 19468281, PMCID: PMC2888928, DOI: 10.1038/mp.2009.50.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsY-BOCS scoresSerotonin reuptake inhibitorsObsessive-compulsive disorderHigh dosesReuptake inhibitorsTreatment respondersDose of SSRIsTreatment efficacyDouble-blind placebo-controlled clinical trialGreater side effect burdenPlacebo-controlled clinical trialSide effect burdenAbsolute risk differenceTreatment of adultsGreater treatment efficacyMajor depressive disorderImproved treatment efficacyTreatment of OCDDose-response relationshipRevMan 4.2.8Clinical trialsDepressive disorderCause dropoutsMean change
2003
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60: 1130-1135. PMID: 12682319, DOI: 10.1212/01.wnl.0000055434.39968.67.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBody WeightChildDiagnostic Techniques, NeurologicalDopamine AntagonistsDose-Response Relationship, DrugDouble-Blind MethodErectile DysfunctionFemaleHeart Conduction SystemHumansMaleMiddle AgedPhobic DisordersRisperidoneSeverity of Illness IndexTicsTourette SyndromeTreatment OutcomeConceptsYale Global Tic Severity ScalePlacebo-controlled trialTotal tic scoreTourette syndromeTic scoreYGTSS total tic scoreCardiac conduction timesSafety of risperidonePrimary outcome measureWeeks of treatmentDurability of efficacyTic Severity ScaleShort-term treatmentMedication-free subjectsPlacebo patientsMedication discontinuationRisperidone groupExtrapyramidal symptomsTic symptomsOutcome measuresDose reductionConduction timeSeverity ScaleTic severityBody weight
1989
Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method.
Riddle MA, Jatlow PI, Anderson GM, Cho SC, Hardin MT, Cohen DJ, Leckman JF. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method. Neuropsychopharmacology 1989, 2: 123-9. PMID: 2742727, DOI: 10.1016/0893-133x(89)90015-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultDebrisoquinDose-Response Relationship, DrugFemaleHomovanillic AcidHumansIsoquinolinesMaleMethodsTourette SyndromeConceptsCentral nervous systemPeripheral HVA productionDebrisoquin sulfatePHVA levelsHomovanillic acidPlasma homovanillic acidCerebrospinal fluid samplesAssessment of reductionDopamine metabolismPlasma concentrationsNervous systemFluid samplesSubstantial inhibitionHVACN metabolismDoseComplete inhibitionDopamineSubjectsInhibitionMetabolismDebrisoquinLevelsPHVA
1981
Induction of rapid mood cycling during L-dopa treatment in a bipolar patient
Ko GN, Leckman JF, Heninger GR. Induction of rapid mood cycling during L-dopa treatment in a bipolar patient. American Journal Of Psychiatry 1981, 138: 1624-1625. PMID: 7304798, DOI: 10.1176/ajp.138.12.1624.Peer-Reviewed Original ResearchMeSH KeywordsBipolar DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansLevodopaMethoxyhydroxyphenylglycolMiddle Aged